Combination Products Office Urges Companies To Call With Their Questions
This article was originally published in The Gray Sheet
Executive Summary
FDA's Office of Combination Products recommends that companies struggling with areas for which there is no clear FDA regulation or guidance consult directly with the office's staff
You may also be interested in...
Concept Papers Seek Industry Input On Combo Product Issues
FDA seeks feedback on two concept papers offering preliminary thoughts on adverse event reporting and on the number of applications needed for a combination product
Cross-Labeling Challenges Lack Easy Fix; Data Exclusivity Incentive Floated
Data exclusivity extensions have been proposed as an incentive to encourage drug firms to amend product labeling in deference to related devices, but FDA and industry reps warn of complications inherent in this strategy
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.